|Videos|November 11, 2017

Preliminary Findings From the NCI-MATCH Trial for Mismatch Repair-Deficient Cancers

Nilofer Azad, MD, associate professor, Johns Hopkins University, discusses preliminary results from the NCI-Match trial for nivolumab (Opdivo) in patients with mismatch repair-deficient cancers The Society for Immunotherapy of Cancer (SITC) 32<sup>nd</sup> Annual Meeting.<br />  

Nilofer Azad, MD, associate professor, Johns Hopkins University, discusses preliminary results from the NCI-Match trial for nivolumab (Opdivo) in patients with mismatch repair-deficient cancers during The Society for Immunotherapy of Cancer (SITC) 32^ndAnnual Meeting.

Stay up to date on practice-changing data in community practice.

Latest CME

Multimedia

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc

Multimedia

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Multimedia

Breaking Down the Rationale for Targeting TROP2 in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Multimedia

Establishing the Rationale for ADC and ICI Combinations in TNBC

Virginia Kaklamani, MD, DSc; Tiffany A. Traina, MD, FASCO

Multimedia

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD

Preliminary Findings From the NCI-MATCH Trial for Mismatch Repair-Deficient Cancers

Related Content

Why ePROs Are the Future of Supportive Oncology Care

Lessons Learned From the OncoPRO Initiative

Dr Patt Reflects on the Evolution of ePRO Monitoring

How Remote Therapeutic Monitoring Enhances Supportive Cancer Care

Future GLP-1 Research Depends on Better Data

Latest CME

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Breaking Down the Rationale for Targeting TROP2 in TNBC

Establishing the Rationale for ADC and ICI Combinations in TNBC

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Louisiana Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Missouri Oncology Society

24th Annual International Congress on the Future of Breast Cancer® East

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

25th Annual International Congress on the Future of Breast Cancer® West

25th Annual International Congress on the Future of Breast Cancer® East

Project ECHO®: Advancing Care in Metastatic TNBC Through PD-L1–Informed Novel Frontline ADC Strategies

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Wisconsin Association of Hematology and Oncology

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Arkansas Association of Cancer Professionals

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Rhode Island Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Iowa Oncology Society

Kansas Society of Clinical Oncology

Satellite Symposia at the Annual Radiation Oncology Meeting

North Carolina Oncology Association

Louisiana Oncology Society

Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

Medical Crossfire®: Mastering the Nuances of Early-Stage HR+/HER2- Breast Cancer—Expert Perspectives on Applying Modern Treatment Paradigms

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

From Frontline to Heavily Pretreated HR+/HER2- Metastatic Breast Cancer: Expert Perspectives on Optimizing the Expanding Treatment Armamentarium

Module 4: Breast Surgery (2025)

Module 5: Breast Radiation Therapy (2025)

Module 3: Pathology And Biomarkers (2025)

Module 6: Adjuvant/Neoadjuvant Chemotherapy and Endocrine Therapy (2025)

Module 1: Breast Carcinogenesis & Management of High-Risk Disease (2025)

Module 7: Systemic Treatment Of Advanced/Metastatic Disease (2025)

Module 2: Breast Imaging (2025)

Module 8: Organ-Targeted Treatment of Metastatic Disease (2025)

Module 9: Toxicity Management And Survivorship Considerations (2025)

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

FDA Approves Iberdomide, the First CELMoD for Relapsed/Refractory Multiple Myeloma

ASTRO Issues Updated Clinical Practice Guideline on RT for Pancreatic Cancer

FAQ: When and How to Discontinue Lenalidomide Maintenance in Multiple Myeloma

With 4 Guideline-Preferred Options, CNS Activity Is Deciding Frontline ROS1+ NSCLC Therapy

Intranasal NEO100 Meets Primary End Point in Recurrent IDH1-Mutant Glioma